Therapeutic Solutions International Inc (TSOI)

[ADVFN_curncman]

$TSOI only pure science based products
One of the major pathologies of COVID-19 is the opening of the endothelial gap junctions allowing for fluid to enter the extracapillary spaces. This results in fluid accumulating in the alveoli, which makes breathing compromised, even in some cases during mechanical ventilation.

The TSOI-576 antibody was administered intravenously into BALB/c mice treated with 100 nanograms of endotoxin per mouse. Endotoxin functions by binding to toll like receptor 4 and causes a pathology that has been reported to be similar to COVID-19 induced ARDS. The lung weight of the animal was measured at time points of zero, 12 hours and 24 hours. Ten mice per group where assessed for the experiment. As can be seen, a significant dose-dependent suppression of pulmonary inflamammation was seen as resulted of the antibody treatment. Additionally, examination of the lungs revealed TSOI-576 also resulted in dose-dependent suppression of neutrophil infiltration, interleukin-6 content in the lung and overall suppression of fibrosis in mice allowed to live 4 weeks and assessed for fibrotic tissue content by hydroxyproline staining.